Operator
Good morning, ladies and gentlemen. Thank you for standing by and welcome to the Agenus Fourth Quarter 2020 Conference Call and Webcast. [Operator Instructions] Please note that this event is being recorded and may be used in future Agenus promotional material.
I would now like to turn the conference over to Jan Medina, Director of Investor Relations. Jan, please go ahead.
Jan Medina
Thanks, Liz, and thank you, all, for joining us today.
Today s call is being webcast and will be available on our website for replay. Before we start, I just want to quickly introduce myself. I now have spoken with a number of you already over the last month or so, but I started year here at Agenus back in February to help lead the investor relations efforts. Certainly, it s a very promising time for the Company. I m looking forward to being part of the conversations we re having with the investment community.
Operator
Welcome to Minerva Neurosciences year-end 2020 conference call. [Operator instructions] There will be a question-and-answer session following today s prepared remarks. This call is being webcast live on the investor section of Minerva s website at ir.minervaneurosciences.com. As a reminder, today s call is being recorded.
I would now like to turn the call over to William Boni, vice president of investor relations and corporate communications at Minerva. Please proceed.
William Boni
Vice President of Investor Relations and Corporate Communications
Good morning. A press release for the company s fourth-quarter and year-end 2020 financial results and business highlights became available at 7:30 Eastern time today and can be found on the investor section of our website. Our annual report on Form 10-K was also filed electronically with the Securities and Exchange Commission this morning and can be found on the SEC s website at www.sec.gov. Joining me on the call today fro
[Operator Instructions]
I would now like to turn the call over to Shari Annes of the Investor Relations group at GlycoMimetics. Please go ahead.
Shari Annes
Thank you. Good morning.
Today, we will review our accomplishments and financial results for both the three and 12-month periods ended December 31, 2020. We ll also update you on recent [Indecipherable]. The press release we issued this morning is available on the company s website at www.glycomimetics.com, under the Investors tab.
This call is being recorded. A dial-in phone replay will be available for 24 hours after the close of the call. The webcast replay will also be available on the Investor Relations section of the company s website for 30 days.
Operator
Welcome to the Fate Therapeutics Fourth Quarter 2020 Financial Results Conference Call. At this time, all participants are in a listen-only mode. This call is being webcast live on the Investors and Media section on Fate s website at fatetherapeutics.com. As a reminder, today s call is being recorded.
I would now like to introduce Scott Wolchko, President and CEO of Fate Therapeutics. The floor is yours.
Scott Wolchko
President and Chief Executive Officer
Thank you. Good afternoon, and thanks everyone for joining us for the Fate Therapeutics fourth quarter 2020 financial results call. Shortly after 4:00 P.M. Eastern Time today, we issued a press release with these results, which can be found on the Investor section of our website under Press Releases. In addition, our Form 10-K for the year ended December 31, 2020 was filed shortly thereafter and can be found on the Investor section of our website under Financial Information.